|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500105617 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-08 08:44:24 |
|
注册时间: Date of Registration: |
2025-07-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超声指导下调节灌注指数对血管介入治疗术后股动脉止血效果的影响 |
|
Public title: |
Effect of ultrasound-guided adjustment of perfusion index on hemostasis of femoral artery after interventional therapy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超声指导下调节灌注指数对血管介入治疗术后股动脉止血效果的影响 |
|
Scientific title: |
Effect of ultrasound-guided adjustment of perfusion index on hemostasis of femoral artery after interventional therapy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
钟伟博 |
研究负责人: |
钟伟博 |
|
Applicant: |
Weibo Zhong |
Study leader: |
Weibo Zhong |
|
申请注册联系人电话: Applicant telephone: |
+86 187 7905 6260 |
研究负责人电话: Study leader's telephone: |
+86 187 7905 6260 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhongweibo@mail.gzsrmyy.com |
研究负责人电子邮件: Study leader's E-mail: |
zhongweibo@mail.gzsrmyy.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江西省赣州市章贡区梅关大道16号 |
研究负责人通讯地址: |
江西省赣州市章贡区梅关大道16号 |
|
Applicant address: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou City, Jiangxi Province |
Study leader's address: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou City, Jiangxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
赣州市人民医院 |
||
|
Applicant's institution: |
Ganzhou People's Hospital |
||
|
研究负责人所在单位: |
赣州市人民医院 |
||
|
Affiliation of the Leader: |
Ganzhou People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJB2025-260-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
赣州市人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ganzhou Peoples Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-02 00:00:00 |
||
|
伦理委员会联系人: |
刘文群 |
||
|
Contact Name of the ethic committee: |
Wenqun Liu |
||
|
伦理委员会联系地址: |
江西省赣州市章贡区梅关大道16号 |
||
|
Contact Address of the ethic committee: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou City, Jiangxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 181 7077 2721 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
赣州市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ganzhou People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江西省赣州市章贡区梅关大道16号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 16 Meiguan Avenue, Zhanggong District, Ganzhou City, Jiangxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Raise independently |
||||||||||||||||||||||
|
Target disease: |
Angiopathy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究我们拟在超声指导下使用PI值来调节加压绷带压力大小,探究血管介入治疗患者在PI值指导下的止血效果。减少患者围术期并发症的发生,加速患者术后康复。 |
||||||||||||||||||||||
|
Objectives of Study: |
We intend to use pI value under the guidance of ultrasound to adjust the pressure of compression bandage, and explore the hemostatic effect of vascular interventional therapy patients under the guidance of PI value. Objective to reduce the incidence of perioperative complications and accelerate the postoperative rehabilitation of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.ASA分级Ⅰ~Ⅲ级; 2.年龄在18-74岁; 3.患者及其家属对研究内容知情同意; 4.右侧股动脉为置管部位。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. ASA classification I.~III. 2. Age 18-74 years old; 3. Patients and their families have informed consent to the content of the study; 4. The right femoral artery is the catheter site. |
||||||||||||||||||||||
|
排除标准: |
1.依从性差,无法完成研究的患者; 2.经研究者判断认为不适合参与本试验的患者; 3.不能进行脚趾Pi值监测者; 4.存在穿刺下肢外周血管疾病; 5.合并有严重的重要脏器功能障碍及血液疾病或免疫系统疾病; 6.凝血功能异常; 7.股动脉穿刺次数>=2次的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with poor compliance and inability to complete the study; 2. Patients who are judged by the investigator to be unsuitable to participate in this trial; 3. Those who cannot monitor the Pi value of the toes; 4. Presence of peripheral vascular disease of the puncture lower limbs; 5. Combined with severe dysfunction of important organs, blood diseases or immune system diseases; 6. Abnormal coagulation function; 7. Patients with femoral artery puncture >=2 times. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-20 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-07-20 00:00:00 至 To 2026-05-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由麻醉实施以及术后数据采集随访以外的第三人(贺婷玉)使用随机数字表法随机均分为超声辅助下使用PI值指导血管介入治疗后股动脉止血组(T组=59)和触摸足背动脉搏动强弱评估下血管介入治疗后股动脉止血组(C组=59)。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A third person (Tingyu He) other than anesthesia implementation and postoperative data collection and follow-up were randomly divided into ultrasound-assisted femoral artery hemostasis group (group t=59) and femoral artery hemostasis group (Group C=59) by using PI value to guide vascular interventional therapy (Group C=59). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲,对随访评估者和患者均设盲 |
|
Blinding: |
The follow-up evaluators and patients were blinded |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用临床试验公共管理平台ResMan (http://www.medresman.org.cn/login.aspx),预计在2026年12月数据完成分析统计后完成数据共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, a public management platform for clinical trials( http://www.medresman.org.cn/login.aspx ),,It is expected that data sharing will be completed after the completion of data analysis and statistics in December 2026. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表记录原始数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Using a case record form to record raw data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |